YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Entera Bio Ltd. Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:…
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immuno…
(RTTNews) - Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for FT839, an off-the-shelf CAR T-cell produc…
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with a Suite of Genetic…
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immuno…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [http…
SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immuno…
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immuno…
[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell…
This article first appeared on GuruFocus. Exploring the Latest 13F Filing and Investment Strategies Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2026, providing insights into his investment mo…
Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items. T…
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following…
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí Bio…
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immun…
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly…
SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Thursday reported a loss of $32.4 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 27 cents. The results matched Wall…
Fate Therapeutics, Inc. Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the f…
New York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells clinical trial analysis repo…
VANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding…
Fate Therapeutics, Inc. SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)…
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery.…
Fate Therapeutics, Inc. FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex…
Fate Therapeutics, Inc. SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline…
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s…
This article first appeared on GuruFocus. Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Warning! GuruFocus has detected 9 Warning Signs with ABBV. Is ABBV fairly valued? Test your thesis with our f…
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items. Th…
Fate Therapeutics, Inc. Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes…
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Con…
Fate Therapeutics, Inc. SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)…
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immuno…
Fate Therapeutics (FATE) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's e…
An updated edition of the Sept. 8, 2025, article. The global cancer treatment market is entering a transformative phase, driven by rising cancer incidence and rapid scientific progress. According to the American Cancer Society, the United…
Incyte (INCY) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items. This q…